# EDGAR Filing Document

**Accession Number:** 0001875558
**File Stem:** 0000000000-23-002789
**Filing Date:** 2023-3
**Character Count:** 3306
**Document Hash:** 744f177ccc426648c93c19562df921f8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002789.hdr.sgml**: 20230426

**ACCESSION NUMBER**: 0000000000-23-002789

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230321

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuvectis Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001875558
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862405608
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 1 BRIDGE PLAZA, SUITE 275
- **CITY:** FORT LEE
- **STATE:** NJ
- **ZIP:** 07024
- **BUSINESS PHONE:** 360-837-7232

**MAIL ADDRESS:**
- **STREET 1:** 1 BRIDGE PLAZA, SUITE 275
- **CITY:** FORT LEE
- **STATE:** NJ
- **ZIP:** 07024
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-23-033910

## Text-Extract

```

United States securities and exchange commission logo

                          March 21, 2023

       Ron Bentsur, M.B.A.
       Chairman, President and Chief Executive Officer
       Nuvectis Pharma, Inc.
       1 Bridge Plaza
       Suite 275
       Fort Lee, NJ 07024

                                                        Re: Nuvectis Pharma,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 17,
2023
                                                            File No. 333-270657

       Dear Ron Bentsur:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Joshua
Gorsky at 202-551-7836 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Matthew W. Mamak, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 21, 2023

Ron Bentsur, M.B.A.
Chairman, President and Chief Executive Officer
Nuvectis Pharma, Inc.
1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024

Re: Nuvectis Pharma, Inc.
Registration Statement on Form S-3
Filed March 17, 2023
File No. 333-270657

Dear Ron Bentsur:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Matthew W. Mamak, Esq.